EBOS Group (NZSE:EBO) Stock Faces Margin Squeeze Despite Bigger Distribution Footprint

EBOS Group stock closed at NZ$23.55 today after investors digested a full year that was more about pressure than celebration. The headline is a squeeze. Underlying EBITDA of A$614m and net profit after tax of A$250m came through while net profit margin over the trailing period stayed at about 1.7%, slightly thinner than a year ago.

The market has already experienced a strong 90 day run in the share price. The key issue now is how much long term value EBOS Group can derive from its new A$360m distribution assets while managing a dividend that currently yields 5.53%.

Is EBOS Group trading at a rare 60% discount to its DCF value, or does the 5.53% dividend coverage risk explain the gap? Compare the current price against our valuation analysis for EBOS Group

FY 2026 Earnings Summary

• Revenue (FY 2026 vs FY 2025 TTM): A$13,486.7m vs A$12,266.9m (higher year on year)
• Net Income (Excl. Extra Items, FY 2026 vs FY 2025 TTM): A$225.2m vs A$215.1m (higher year on year)
• Basic EPS (Earnings Per Share, FY 2026 vs FY 2025 TTM): A$1.098 vs A$1.097234 (broadly stable year on year)
• Net Profit Margin (FY 2026 vs FY 2025 TTM): 1.7% vs 1.8% (slightly thinner margin)

Prefer clear visuals instead of another wall of numbers and earnings tables? See EBOS Group’s full financial picture, including how its dividend track record fits alongside revenue and profit trends, in the interactive company report for EBOS Group.

EBOS bullish thesis meets key execution checkpoints

Bulls argue EBOS Group’s heavy spend on new distribution centres should now translate into higher throughput, better margins and more cash from a larger base in healthcare and animal care. FY26 goes some distance toward that story. The A$360m DC rollout is complete and Kemps Creek is already about 20% more productive than the site it replaced, with a 30% uplift targeted by FY27. That directly supports the claim that automation can offset pressure from lower percentage margins on high value medicines.

Revenue of A$13.5b and underlying EBITDA of A$614m show the bigger network is being used, not just built. Healthcare EBITDA of A$516m, despite fuel and FX headwinds, and Animal Care EBITDA of A$138m on A$907m revenue, indicate the tilt toward higher return segments is visible in the mix. The maintained dividend and net leverage at 2.1x suggest the balance sheet is coping with the investment phase.

Access the multi year earnings and cash flow analyst estimates for EBOS Group

EBOS bearish worries on margins not fully cleared

The cautious view on EBOS Group is that a heavier mix of high value, low percentage margin medicines and fierce pharmacy wholesale competition will slowly erode profitability and expose an uncovered dividend. This result gives bears some support. Group net profit margin is flat at 1.7% compared with 1.8% in the prior period, so the large investment in A$360m of distribution assets has not yet translated into a clear margin uplift. Healthcare EBITDA grew more slowly than segment revenue and management acknowledged fuel, FX and new pricing arrangements as headwinds, which points to limited pricing power for now.

At the same time, the dividend is maintained and net leverage sits at 2.1x, inside the 1.7x to 2.3x target. That means the feared balance sheet stretch is not yet visible, although a higher payout is being supported without clear margin expansion so far.

After a 5.53% dividend yield supported by relatively thin margins and recent heavy capex, it is fair to ask whether this is the only pressure point investors should worry about or if other structural issues might be buried in the detail. Review the independent risk scoring and potential hidden pressure points flagged in our risk analysis for EBOS Group which shows 1 important warning sign.

Take Control Of Your Next Move

If the mix of thin margins, new A$360m distribution assets and a 5.53% dividend yield has you watching EBOS Group closely, register for free with Simply Wall St and add it to a Watchlist to track price against fair value and spot a price that fits your plan. Once you own it, keep your decisions clear with the Portfolio Command Center that focuses on key developments across your holdings instead of daily noise. For a longer term view, compare your thinking with other investors by joining the Community and seeing a range of perspectives on EBOS Group and similar stocks. This way you uncover potential catalysts and risks early and give yourself a better chance of staying ahead of the market.

Seeking Alternatives Beyond EBOS Group?

Fresh opportunities move fast as momentum builds, prices fly or drop and stories get caught before the crowd notices. Scan these under the radar ideas while it matters and act now.

• Spot potential breakout compounders early by scanning a curated set of 612 high quality undiscovered gems before they move out of reach and sentiment shifts away from under the radar opportunities.
• Target resilience and sleep easier by reviewing hand picked 283 resilient stocks with low risk scores that aim to balance steadier fundamentals with ongoing momentum while the market focus is still elsewhere.
• Ride structural shifts in energy demand by checking carefully filtered 92 nuclear energy infrastructure stocks that could benefit if capital keeps flowing into critical infrastructure projects.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com